Skip to content
DraconiticResearch
Search Sources API
182,460 studies31 sourcesUpdated 19 min ago
Peer-reviewedCC BY 4.0Communications Medicine

OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer

  • Christoph Schultheiß1,2
  • Brenda Besemer1,2
  • Edith Willscher3
  • Lisa Paschold3
  • Tifanny Mersceman4
  • Alice Talpin4
  • Clara Serger1,5
  • Alfred Zippelius1,5
  • Alfredo Berruti6
  • Salvatore Grisanti6
  • Catharina Willemien Menke-van der Houven van Oordt7
  • Eric Baudin8
12 more authors
  • Laura-Sophie Landwehr9
  • Jaume Capdevila10
  • Vivek Subbiah11
  • Dan Granberg12
  • Kirsten Gedske Daugaard13
  • Alexandra Triebig14
  • Thibault Gauduchon15
  • Christine Do Cao16
  • Marie-Eve Garcia17
  • Joao Magalhaes4
  • Laurent Chêne4
  • Mascha Binder1,2,18
18 affiliations
  1. 1Division of Medical Oncology, University Hospital Basel, Basel, Switzerland
  2. 2Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland
  3. 3Department of Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany
  4. 4Enterome SA, Paris, France
  5. 5Laboratory of Cancer Immunology, Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
  6. 6Università degli Studi di Brescia, Azienda Ospedaliera Spedali Civili, Brescia, Italy
  7. 7Department of Medical Oncology, Amsterdam UMC, Cancer Centre Amsterdam, Amsterdam, The Netherlands
  8. 8Endocrine Oncology, Gustave Roussy, Villejuif, France
  9. 9Internal Medicine, University Hospital Würzburg, Würzburg, Germany
  10. 10Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
  11. 11Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA USA
  12. 12Department of Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Karolinska University Hospital Solna, Stockholm, Sweden
  13. 13Medical Oncology, Rigshospitalet/University Hospital, Copenhagen, Denmark
  14. 14Medicine IV Endocrine Oncology, Ludwig Maximilians University of Munich, München, Germany
  15. 15Medical Oncology, Centre Léon Bérard, Lyon, France
  16. 16University Hospital Lille - Hôpital Claude Huriez, Lille, France
  17. 17Hospital Nord, Marseille, France
  18. 18Collaborative Research Institute Intelligent Oncology (CRIION), Freiburg, Germany
Read full textPDFDOICite

Abstract

Background: Patients with advanced malignant adrenal tumors face poor prognoses with limited treatment options. Emerging data suggest that these rare tumors exhibit immunogenicity, potentially benefiting from intensified immunotherapy.

Methods: The SPENCER trial (NCT04187404) evaluates EO2401, an off-the-shelf in vivo peptide immunotherapy containing three synthetic HLA-A*02 restricted-peptides called OncoMimic and derived from human gut commensals that exhibit molecular mimicry to tumor-associated antigens (BIRC5, FOXM1, IL13RA2) combined with nivolumab in patients with locally advanced or metastatic adrenocortical carcinoma (ACC) or malignant pheochromocytoma/ paraganglioma (PPGL). We performed T cell receptor (TCR) repertoire sequencing to profile the TCR architecture in ACC and characterize vaccination imprints.

Results: Here we show that ACC patients are characterized by a restricted peripheral T cell richness. EO2401 does not expand highly shared TCR clones across patients but diversifies pre-existing T cell clusters. These clusters are not converging on known neoantigen-specific TCRs but exhibit generation probabilities characteristic of public clones some of which being shared across patients.

Conclusions: These findings suggest that EO2401-based peptide immunotherapy combined with checkpoint inhibition can broaden and activate public, pre-existing T cell clusters, potentially enhancing tumor-specific immune responses.

Related

  1. 524 Zopapogene imadenovec-drba, a novel adenovector-based immunotherapy, induces complete and durable responses in recurrent respiratory papillomatosis
    Helen Sabzevari, Amy Lankford, Gaetano Bonifacio +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYImmunologyOncologyDOAJ
  2. An automated operon refactoring workflow for heterologous expression of non-ribosomal peptide biosynthetic gene clusters
    Zhibo Li, Lifu Liu, Xingyan Sun +15
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textPharmacology & toxicologyCrossref
  3. A novel oncolytic peptide synergizing with immunotherapy
    Guido Kroemer, Xiaolian Deng, Baldur Sveinbjørnsson +1
    OncoImmunologyPeer-reviewedCC BY 4.0Full textOncologyHAL
  4. Symptom clusters and symptom network characteristics in chronic fatigue syndrome patients: a cross-sectional study
    Aiqun Zi, Yihan Zhang, Min Sun +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy
    Jiangmin Zhou, Huifang Xiong, Honghao Zhou +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{schultheiß2026oncomimic,
  title = {{OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer}},
  author = {Christoph Schultheiß and Brenda Besemer and Edith Willscher and Lisa Paschold and Tifanny Mersceman and Alice Talpin and Clara Serger and Alfred Zippelius and Alfredo Berruti and Salvatore Grisanti and Catharina Willemien Menke-van der Houven van Oordt and Eric Baudin and Laura-Sophie Landwehr and Jaume Capdevila and Vivek Subbiah and Dan Granberg and Kirsten Gedske Daugaard and Alexandra Triebig and Thibault Gauduchon and Christine Do Cao and Marie-Eve Garcia and Joao Magalhaes and Laurent Chêne and Mascha Binder},
  journal = {Communications Medicine},
  year = {2026},
  month = jul,
  doi = {10.1038/s43856-026-01755-8},
  url = {https://doi.org/10.1038/s43856-026-01755-8},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - OncoMimic peptide-based immunotherapy EO2401 induces shared T cell clusters in patients with adrenal cancer
AU  - Christoph Schultheiß
AU  - Brenda Besemer
AU  - Edith Willscher
AU  - Lisa Paschold
AU  - Tifanny Mersceman
AU  - Alice Talpin
AU  - Clara Serger
AU  - Alfred Zippelius
AU  - Alfredo Berruti
AU  - Salvatore Grisanti
AU  - Catharina Willemien Menke-van der Houven van Oordt
AU  - Eric Baudin
AU  - Laura-Sophie Landwehr
AU  - Jaume Capdevila
AU  - Vivek Subbiah
AU  - Dan Granberg
AU  - Kirsten Gedske Daugaard
AU  - Alexandra Triebig
AU  - Thibault Gauduchon
AU  - Christine Do Cao
AU  - Marie-Eve Garcia
AU  - Joao Magalhaes
AU  - Laurent Chêne
AU  - Mascha Binder
PY  - 2026
DA  - 2026/07/06
JO  - Communications Medicine
DO  - 10.1038/s43856-026-01755-8
UR  - https://doi.org/10.1038/s43856-026-01755-8
AB  - Background: Patients with advanced malignant adrenal tumors face poor prognoses with limited treatment options. Emerging data suggest that these rare tumors exhibit immunogenicity, potentially benefiting from intensified immunotherapy.  Methods: The SPENCER trial (NCT04187404) evaluates EO2401, an off-the-shelf in vivo peptide immunotherapy containing three synthetic HLA-A*02 restricted-peptides called OncoMimic and derived from human gut commensals that exhibit molecular mimicry to tumor-associated antigens (BIRC5, FOXM1, IL13RA2) combined with nivolumab in patients with locally advanced or metastatic adrenocortical carcinoma (ACC) or malignant pheochromocytoma/ paraganglioma (PPGL). We performed T cell receptor (TCR) repertoire sequencing to profile the TCR architecture in ACC and characterize vaccination imprints.  Results: Here we show that ACC patients are characterized by a restricted peripheral T cell richness. EO2401 does not expand highly shared TCR clones across patients but diversifies pre-existing T cell clusters. These clusters are not converging on known neoantigen-specific TCRs but exhibit generation probabilities characteristic of public clones some of which being shared across patients.  Conclusions: These findings suggest that EO2401-based peptide immunotherapy combined with checkpoint inhibition can broaden and activate public, pre-existing T cell clusters, potentially enhancing tumor-specific immune responses.
SN  - 2730-664X
ER  -